Diabetes Core Update Special Edition - SGLT2 Inhibitors Part 3: Beneficial Effects on Heart Failure Endpoints– March 2021
In this third episode of a three-part series on SGLT-2 inhibitors Drs. John Russell and Neil Skolnik discuss the effects of the SGLT-2 inhibitors in heart failure in persons with and without diabetes. In episode 1, Drs. Russell and Skolnik discussed an overview of the CVOTs for the SGLT-2 inhibitors and in episode 2 they focused on renal outcomes. This special three-part series is supported by independent educational grant from AstraZeneca. For more information about each of ADA’s science and medical journals, please visit www.diabetesjournals.org. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Director, Family Medicine Residency Program, Chair-Department of Family Medicine, Abington Jefferson Health